Open Access
Issue
Med Sci (Paris)
Volume 34, Number 12, Décembre 2018
Page(s) 1056 - 1062
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2018297
Published online 09 January 2019
  1. Arnal JF, Lenfant F, Metivier R, et al. Membrane and nuclear estrogen receptor alpha actions: From tissue specificity to medical implications. Physiol Rev 2017 ; 97 : 1045–1087. [CrossRef] [PubMed] [Google Scholar]
  2. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015 ; 100 : 3975–4011. [CrossRef] [PubMed] [Google Scholar]
  3. Portman DJ, Gass ML. Vulvovaginal atrophy terminology consensus conference panel. genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American menopause society. Menopause 2014 ; 21 : 1063–1068. [CrossRef] [PubMed] [Google Scholar]
  4. de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013 ; 16 : 316–337. [CrossRef] [PubMed] [Google Scholar]
  5. Behl C.. Oestrogen as a neuroprotective hormone. Nat Rev Neurosci 2002 ; 3 : 433–442. [CrossRef] [PubMed] [Google Scholar]
  6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 ; 288 : 321–333. [CrossRef] [PubMed] [Google Scholar]
  7. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004 ; 291 : 1701–1712. [CrossRef] [PubMed] [Google Scholar]
  8. Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol 2017 ; 13 : 220–231. [CrossRef] [PubMed] [Google Scholar]
  9. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012 ; 345 : e6409. [CrossRef] [Google Scholar]
  10. Scarabin PY. Hormones and venous thromboembolism among postmenopausal women. Climacteric 2014 ; 17 : Suppl 2 34–37. [CrossRef] [PubMed] [Google Scholar]
  11. Renoux C. Dell’aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010 ; 340 : c2519. [CrossRef] [Google Scholar]
  12. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010 ; 126 : 5–11. [CrossRef] [PubMed] [Google Scholar]
  13. Olie V, Plu-Bureau G, Conard J, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011 ; 18 : 488–493. [CrossRef] [PubMed] [Google Scholar]
  14. Komm BS, Mirkin S, Jenkins SN. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss. Steroids 2014 ; 90 : 71–81. [CrossRef] [PubMed] [Google Scholar]
  15. Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 2011 ; 12 : 496–503. [CrossRef] [PubMed] [Google Scholar]
  16. Grainger DJ, Schofield PM. Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence. Circulation 2005 ; 112 : 3018–3024. [CrossRef] [PubMed] [Google Scholar]
  17. D’Amelio P, Isaia GC. The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother 2013 ; 14 : 949–956. [CrossRef] [PubMed] [Google Scholar]
  18. Martinkovich S, Shah D, Planey SL, Arnott JA. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clin Interv Aging 2014 ; 9 : 1437–1452. [Google Scholar]
  19. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006 ; 295 : 2727–2741. [CrossRef] [PubMed] [Google Scholar]
  20. Kim JH, Meyers MS, Khuder SS, et al. Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice. Mol Metab 2014 ; 3 : 177–190. [CrossRef] [PubMed] [Google Scholar]
  21. Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005 ; 146 : 3999–4008. [CrossRef] [PubMed] [Google Scholar]
  22. Lewis-Wambi JS, Kim H, Curpan R, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol 2011 ; 80 : 610–620. [CrossRef] [PubMed] [Google Scholar]
  23. Buscato M, Fontaine C, Fabre A, et al. The antagonist properties of Bazedoxifene after acute treatment are shifted to stimulatory action after chronic exposure in the liver but not in the uterus. Mol Cell Endocrinol 2018 ; 472 : 87–96. [CrossRef] [PubMed] [Google Scholar]
  24. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008 ; 23 : 1923–1934. [CrossRef] [PubMed] [Google Scholar]
  25. Mirkin S, Komm BS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas 2013 ; 76 : 213–220. [CrossRef] [PubMed] [Google Scholar]
  26. Harvey JA, Pinkerton JV, Baracat EC, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause 2013 ; 20 : 138–145. [PubMed] [Google Scholar]
  27. De Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011 ; 22 : 567–576. [CrossRef] [PubMed] [Google Scholar]
  28. Skouby SO, Pan K, Thompson JR, et al. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial. Menopause 2015 ; 22 : 640–649. [CrossRef] [PubMed] [Google Scholar]
  29. Chang KC, Wang Y, Bodine PV, et al. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010 ; 118 : 117–124. [CrossRef] [PubMed] [Google Scholar]
  30. Peano BJ, Crabtree JS, Komm BS, et al. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009 ; 150 : 1897–1903. [CrossRef] [PubMed] [Google Scholar]
  31. Komm BS, Mirkin S. Evolution of the tissue selective estrogen complex (TSEC). J Cell Physiol 2013 ; 228 : 1423–1427. [CrossRef] [Google Scholar]
  32. Borjesson AE, Windahl SH, Lagerquist MK, et al. Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone. Proc Natl Acad Sci USA 2011 ; 108 : 6288–6293. [CrossRef] [Google Scholar]
  33. Billon-Gales A, Krust A, Fontaine C, et al. Activation function 2 (AF2) of estrogen receptor-alpha is required for the atheroprotective action of estradiol but not to accelerate endothelial healing. Proc Natl Acad Sci USA 2011 ; 108 : 13311–13316. [CrossRef] [Google Scholar]
  34. Adlanmerini M, Solinhac R, Abot A, et al. Mutation of the palmitoylation site of estrogen receptor alpha in vivo reveals tissue-specific roles for membrane versus nuclear actions. Proc Natl Acad Sci USA 2014 ; 111 : E283–E290. [CrossRef] [Google Scholar]
  35. Guillaume M, Handgraaf S, Fabre A, et al. Selective activation of estrogen receptor alpha activation function-1 is sufficient to prevent obesity, steatosis, and insulin resistance in mouse. Am J Pathol 2017 ; 187 : 1273–1287. [CrossRef] [PubMed] [Google Scholar]
  36. Fontaine C, Abot A, Billon-Gales A, et al. Tamoxifen elicits atheroprotection through estrogen receptor alpha AF-1 but does not accelerate reendothelialization. Am J Pathol 2013 ; 183 : 304–312. [CrossRef] [PubMed] [Google Scholar]
  37. Harrington WR, Kim SH, Funk CC, et al. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol 2006 ; 20 : 491–502. [CrossRef] [PubMed] [Google Scholar]
  38. Chambliss KL, Wu Q, Oltmann S, et al. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 2010 ; 120 : 2319–2330. [CrossRef] [PubMed] [Google Scholar]
  39. Madak-Erdogan Z, Kim SH, Gong P, et al. Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues. Sci signal 2016; 9 : ra53. [CrossRef] [Google Scholar]
  40. Mawet M, Maillard C, Klipping C, et al. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur J Contracept Reprod Health Care 2015 ; 20 : 463–475. [PubMed] [Google Scholar]
  41. Coelingh Bennink HJ, Heegaard AM, Visser M, et al. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric 2008 ; 11 : Suppl 1 2–14. [CrossRef] [PubMed] [Google Scholar]
  42. Abot A, Fontaine C, Buscato M, et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation. EMBO Mol Med 2014 ; 6 : 1328–1346. [CrossRef] [PubMed] [Google Scholar]
  43. Visser M, Kloosterboer HJ, Bennink HJ. Estetrol prevents and suppresses mammary tumors induced by DMBA in a rat model. Horm Mol Biol Clin Investig 2012 ; 9 : 95–103. [PubMed] [Google Scholar]
  44. Apter D, Zimmerman Y, Beekman L, et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). Contraception 2016 ; 94 : 366–373. [CrossRef] [PubMed] [Google Scholar]
  45. Holinka CF, Brincat M. Coelingh Bennink HJ. Preventive effect of oral estetrol in a menopausal hot flush model. Climacteric 2008 ; 11 : suppl 1 15–21. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.